Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

2014年12月， 复旦大学附属肿瘤医院 在Oncotarget期刊上发表了一篇论文。在 发表4年后 ，因 图片组内重复 在pubpeer上被读者质疑。 论文题为 “Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor ...

Azothbio Inc. and Daegu-Gyeongbuk Medical Innovation Foundation have described non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune disease, ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Panelists discuss how distinct safety profiles among Bruton tyrosine kinase (BTK) inhibitors—including variations in cardiovascular effects, bleeding risk, infection susceptibility, and other adverse ...